IL17A and psoriasis: In this context, the study by Yeh et al. [19] provides very interesting results, showing significantly greater changes in the gut microbiome of patients with psoriasis treated with secukinumab (interleukin-17 inhibitor) compared to ustekinumab (inhibitor of interleukin-12 and -23).